Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic Malignancies


Release Date: April 30, 2018
Expiration Date: April 30, 2019
Media: Internet - based

 

Activity Overview

This online activity will feature an overview of chimeric antigen receptor (CAR) T cells, including the mechanism of action, key clinical data, and the future direction of CAR T-cell therapy. The format for this Oncology Consultations™ will include 3 modules in a “fireside chat” format during which clinical evidence will be discussed, along with explanations of implications for physician practice.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

CME Activity Table of Contents

  • Pretest
  • Module 1. Biology Behind CAR T-Cell Therapies
  • Module 2. Crossfire Discussion: Application of CAR T-Cell Data
  • Module 3. What Lies Ahead for CAR T Cells?
  • Posttest

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video Files” will be available for your reference.
  • To receive a CME certificate, participants must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, hematologists, and fellows who treat patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Contrast the mechanism of action of CAR T cells with those of other therapeutic options in the treatment of hematologic malignancies
  2. Summarize recent clinical trial data concerning the application of CAR T-cell strategies in the management of hematologic malignancies
  3. Appraise the potential role of CAR T-cell therapies in evolving treatment paradigms for hematologic malignancy management
  4. Describe appropriate techniques to identify and manage different treatment-related toxicities in the care of patients who receive CAR T-cell therapies

Faculty, Staff, and Planners' Disclosures

Moderator

Anas Younes, MD
Professor and Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Grant/Research Support: Novartis, J&J, Curis, Roche, Bristol-Myers Squibb; Other Support – Honoraria for Speaking Engagements: Bayer, Bristol-Myers Squibb, Celgene, Incyte, Janssen, Sanofi, Seattle Genetics, Takeda Millennium, Genentech, Merck

Faculty

Reiner J. Brentjens, MD, PhD
Director, Cellular Therapeutics
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosure: Grant/Research Support: Juno Therapeutics; Consultant: Juno Therapeutics

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse Recap™

PER Pulse Recap (1 of 3)

In this online continuing medical education (CME)‒certified activity, Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic Malignancies, expert faculty Anas Younes, MD, and Reiner J. Brentjens, MD, PhD, discuss the evolving landscape of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies, including mechanisms of action, key clinical data, and future directions.
 
This first of 3 PER Pulse™ Recaps summarizing the online webcast focuses on the biology behind CAR T-cell therapies. Below are some highlights from the activity featuring Drs. Younes and Brentjens:
  • An overview of the mechanism of action of CAR T-cell therapy, including first-generation CARs and the advantages afforded by second-generation constructs
  • Discussion of the CAR T-cell therapy process, the parties involved, and how to integrate it into clinical practice
  • Expert commentary about optimal strategies for CAR T-cell therapy dosing and infusions
“The [CAR T-cell] construct is universal. The same chimeric antigen receptor would work in your cells, as well as my cells, as well as anyone’s cells. On top of that, it works both in helper cells (CD4 cells) as well as cytotoxic cells (CD8 cells). And it certainly appears right now that both populations are important for the outcome that patients have.”
 — Reiner J. Brentjens, MD, PhD

PER Pulse Recap (2 of 3)

As a follow-up to this online continuing medical education (CME)‒certified activity, Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic Malignancies, with Anas Younes, MD, and Reiner J. Brentjens, MD, PhD, this second of 3 PER Pulse™ Recaps summarizing the online program focuses on current and emerging applications of chimeric antigen receptor (CAR) T-cell data in hematologic malignancies. Below are some highlights from the activity featuring Drs. Younes and Brentjens:
  • A discussion of the use of CAR T-cell therapy in acute lymphocytic leukemia (ALL), including the US Food and Drug Administration (FDA) approval of tisagenlecleucel in adults with relapsed/refractory (R/R) B-cell ALL, and data from the phase II ELIANA trial showing durable remission rates in pediatric and young adult patients with B-cell ALL
  • Expert commentary on the use of CAR T-cell therapy in lymphoma and critical evaluation of relative clinical trial data, including:
    • The phase I/II ZUMA-1 trial of conditioning chemotherapy plus axicabtagene ciloleucel in patients with refractory diffuse large B-cell lymphoma (DLBCL), which demonstrated a >80% overall response rate (ORR) and a 49% complete response rate at ≥6 months of follow-up
    • The JULIET trial investigating tisagenlecleucel for patients with R/R DLBCL, which demonstrated a 53% ORR
  • Early data from a phase I study of bb2121 anti-BCMA CAR T-cell therapy for patients with refractory multiple myeloma that demonstrated durable remissions and a 9-month progression-free survival rate of 71%
  • An overview of the toxicities of CAR T-cell therapy and approaches to supportive care before, during, and after treatment to manage these adverse events for patients, for example, twice-daily assessment for cytokine release syndrome, the toxicity most commonly experienced by patients receiving CAR T-cell therapy.
“[In the ZUMA-1 trial] you have cell therapy giving you about 80% response rate, and close to 50% with a complete response (CR) rate. Of course, we need longer-term follow-up, but almost half of them are still in CR, which is remarkable. How many of those will be cured? It’s too early to call. But I wouldn’t be surprised that some of these patients could potentially be cured with this simple cell therapy.”
 — Anas Younes, MD

PER Pulse Recap (3 of 3)

As a follow-up to this online continuing medical education (CME)‒certified activity, Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic Malignancies, with Anas Younes, MD, and Reiner J. Brentjens, MD, PhD, this third of 3 PER Pulse™ Recaps summarizing the online program focuses on the future landscape of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies. Below are some highlights from the activity featuring Drs. Younes and Brentjens:
  • Next steps in the development of CAR T-cell therapy, including how to improve CAR T-cell persistence and increase the durability of disease eradication
  • The potential role of CAR T-cell therapy in earlier lines of treatment and in patients with minimal residual disease, as well as its expanded use and decreasing cost
  • Expert commentary on the future of combination treatments with CAR T-cell therapy
“We have two very promising stories [in CAR T-cell therapy]: the multiple myeloma story and the B-cell malignancy story. Within that, we still need to improve; we still need to come up with better types of CAR T cells that can persist longer, that have better cytotoxicity, that can eradicate disease better.”
 — Reiner J. Brentjens, MD, PhD

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the archived Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic Malignancies.






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By